Program
cretostimogene grenadenorepvec
Also written as “Cretostimogene Grenadenorepvec”, “CG0070” and “oncolytic adenovirus expressing GMCSF”.
Its studies are mostly in Non-Muscle Invasive Bladder Neoplasms · Urinary Bladder Neoplasms · Carcinoma, Transitional Cell, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| CG Oncology | 63 open or running | phase 3since Jun 26, 2020 | May 19, 2014 | Nov 2026phase 3 · NCT06111235 |
| Cell Genesys | 10 open or running | phase 1since May 2, 2005 | May 2, 2005 | none ahead |
| Lepu Biopharma | 11 open or running | phase 2since Dec 6, 2025 | Dec 6, 2025 | Dec 31, 2027phase 2 · NCT07283835 |
Also a collaborator on its studies: Merck.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 2, 2005First study: phase 1 study in Carcinoma, Transitional CellNew to Cell GenesysCell Genesys · NCT00109655 · 75 enrolled · United States, Canada
- May 19, 2014CG Oncology's first study: phase 2 study in Urinary Bladder NeoplasmsNew to CG OncologyCG Oncology · NCT02143804 · United States
- Feb 9, 2015Phase 2 study in Urinary Bladder NeoplasmsCG Oncology · NCT02365818 · 66 enrolled · United States
- May 5, 2020Phase 2 study in Non-Muscle Invasive Bladder NeoplasmsCG Oncology · NCT04387461 · 35 enrolled · United States, Korea, Republic of
- Jun 26, 2020Phase 3 study in Non-Muscle Invasive Bladder NeoplasmsCG Oncology · NCT04452591 · 190 enrolled · United States, Australia, Canada and more
- Oct 25, 2023Phase 3 study in Non-Muscle Invasive Bladder NeoplasmsCG Oncology · NCT06111235 · 367 enrolled · United States, Canada
- Aug 14, 2024Phase 2 study in Urinary Bladder NeoplasmsCG Oncology · NCT06567743 · 325 planned · United States, Canada
- Dec 6, 2025Lepu Biopharma's first study: phase 2 study in Non-Muscle Invasive Bladder NeoplasmsNew to Lepu BiopharmaLepu Biopharma · NCT07283835 · 16 planned · China
Ahead
- Nov 2026Primary completion: phase 3 study in Non-Muscle Invasive Bladder NeoplasmsCG Oncology · NCT06111235
- Mar 31, 2027Primary completion: phase 2 study in Urinary Bladder NeoplasmsCG Oncology · NCT06567743
- Dec 31, 2027Primary completion: phase 2 study in Non-Muscle Invasive Bladder NeoplasmsLepu Biopharma · NCT07283835
- Jun 16, 2030Primary completion: phase 3 study in Non-Muscle Invasive Bladder NeoplasmsCG Oncology · NCT04452591
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07283835Non-Muscle Invasive Bladder Neoplasms · China | 2 | Recruiting | Lepu Biopharma | Dec 31, 2027 | 16 |
| NCT06567743Urinary Bladder Neoplasms · United States, Canada | 2 | Recruiting | CG Oncology | Mar 31, 2027 | 325 |
| NCT06111235Non-Muscle Invasive Bladder Neoplasms · United States, Canada | 3 | Active, not recruiting | CG Oncology | Nov 2026 | 367 |
| NCT04452591Non-Muscle Invasive Bladder Neoplasms · United States, Australia, Canada and more | 3 | Active, not recruiting | CG Oncology | Jun 16, 2030 | 190 |
| NCT04387461Non-Muscle Invasive Bladder Neoplasms · United States, Korea, Republic of | 2 | Completed | CG Oncology | Mar 7, 2023 | 35 |
| NCT02365818Urinary Bladder Neoplasms · United States | 2 | Completed | CG Oncology | Aug 2018 | 66 |
| NCT02143804Urinary Bladder Neoplasms · United States | 2 | Withdrawn | CG Oncology | Mar 2015 | 0 |
| NCT00109655Carcinoma, Transitional Cell · United States, Canada | 1 | UNKNOWN | Cell Genesys | Oct 2008 | 75 |
How it is read
Names in the registry
- “Cretostimogene Grenadenorepvec”, 4 entries
- “CG0070”, 2 entries
- “oncolytic adenovirus expressing GMCSF”, 1 entry
- “Oncolytic adenovirus (serotype 5) - CG0070”, 1 entry
Codes read as this program: CG0070.
Conditions, from the studies’ own filings
- Non-Muscle Invasive Bladder Neoplasms, 4 studies
- Urinary Bladder Neoplasms, 3 studies
- Carcinoma, Transitional Cell, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.